Biogen Inc. (BIIB) stock prices updated...
 

Biogen Inc. stock price, BIIB

Biogen Inc. stock chart:



Biogen Inc. close price: 254.84

Stock price forecast:

UP TO +1.34%
Target: 258.25

Total forecasts: 90
Reached: 12 (13.33%)

Total Win: 63.19 (23.32%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%
90911314.29%75.510.30%19,891.93-14.41-0.07%61.100.26%
303100.00%0.000.00%7,900.040.000.00%0.000.00%
141500.00%0.000.00%3,822.600.000.00%0.000.00%
7800.00%0.000.00%2,038.720.000.00%0.000.00%

Showing 1-10 of 541 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date
2017-07-25254.84258.280000-00-00
2017-07-24254.84258.970000-00-00
2017-07-23254.84257.950000-00-00
2017-07-22254.84258.170000-00-00
2017-07-21254.84258.390000-00-00
2017-07-20254.84257.970000-00-00
2017-07-19254.84258.120000-00-00
2017-07-18254.84258.20000-00-00
2017-07-17254.84258.220000-00-00
2017-07-16254.84258.980000-00-00

Biogen Inc. latest news:


  • 07/25/2017 10:22:36

    UPDATE 3-After strong quarter, Biogen rolls out growth strategy

    * Spinraza sales of $203 mln smash analyst estimates of $70 mln

  • 07/25/2017 05:11:49

    Biogen stock surges nearly 6% on Q2 profit, revenue beats

    Biogen Inc.(BIIB) shares surged 5.8% in premarket trade Tuesday after the company reported second-quarter profit and revenue beats. Earnings for the latest quarter fell to $863 million, or $4.07 per share, from $1.05 billion, or $4.79 per share in the year-earlier period. Adjusted earnings-per-share were $5.04, compared with the FactSet consensus of$ 4.37.

  • 06/19/2017 12:43:32

    Biogen's stock jumps after UBS boosts rating, price target

    Shares of Biogen Inc. ran up 3.9% in afternoon trade Monday, to turn positive on the year, after UBS backed away from its bearish rating on the belief valuation may have bottomed. Analyst Carter Gould raised his rating to neutral from sell and raised his stock price target to $270, which is 3.2% above current levels, from $262. The stock is now up 0.2% year to date, while the iShares Nasdaq Biotechnology ETF has run up 13.1% and the S&P 500 has gained 9.4%. Gould said concerns over competition to Biogen's Spinraza for spinal muscular atrophy from gene therapy is already priced into the stock price, and sentiment has neared a bottom after the departure of its chief financial officer last week. Gould said he is also "more constructive" on Biogen's aducanumab Alzheimer's treatment. Although he believes intensifying competition will continue to weigh on the company's multiple sclerosis franchise, but he sees that "increasingly balanced by a growing focus on aducanumab."Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 06/14/2017 15:28:49

    Biogen and Anadarko slump while H&R Block and Southern rise

    Biogen and Anadarko Petroleum fall while H&R Block and Southern trade higher

  • 06/13/2017 14:47:41

    Alexion names Biogen's Paul Clancy as CFO

    Alexion Pharmaceuticals Inc(ALXN) on Tuesday named Biogen Inc's Chief Financial Officer Paul Clancy as its finance head, effective July 31. Clancy will succeed Dave Anderson, who will remain with Alexion until August end, the company said. Alexion shares were up 3.7 percent in extended trading while Biogen shares were down 1.9 percent.

  • 06/13/2017 14:45:33

    Alexion hires Biogen executive to serve as its CFO

    Shares of Alexion Pharmaceuticals Inc. rose more than 2% late Tuesday after the company announced the hiring of the former Biogen Inc. chief financial officer as its CFO. Paul J. Clancy will join Alexion on July 31 after having served as Biogen's CFO for the past 10 years, the company said in a statement. Clancy succeeds Dave Anderson, who will continue to serve as CFO until July 31. "To ensure a smooth transition, (Anderson) will then become a Senior Advisor to the Chief Executive Officer and will remain with Alexion until the end of August," the company said in a statement. Shares of Biogen fell 1.8%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 04/28/2017 12:20:00

    What's Worrying Me About Biogen

    Biogen could struggle to maintain its market-leading position in multiple sclerosis over the next two years.

  • More trends:

    Biolase, Inc.BIOL | BioLife Solutions, Inc.BLFS | BioLineRx Ltd.BLRX | BioMarin Pharmaceutical Inc.BMRN | BiondVax Pharmaceuticals Ltd.BVXV | BiondVax Pharmaceuticals Ltd.BVXVW | Bio-Path Holdings, Inc.BPTH | BioScrip, Inc.BIOS | BioShares Biotechnology Clinical Trials FundBBC | BioShares Biotechnology Products FundBBP |